Clinical Trial Update: Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects [Phase 4]

View source ↗

Summary

A Phase 4 pediatric trial comparing twice-daily versus once-daily dosing of pimecrolimus 1% cream for atopic dermatitis has completed. The study assessed whethe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Novartis | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED